U.K. looks to shake up trial, medicines regulation amid Brexit

Red telephone booths in front of Christmas decorations lights in London, United Kingdom
A bill affecting the pharma industry was brought forward by the U.K.'s newly elected government just before Christmas. (Photo by SHansche/iStock/Getty Images Plus/Getty Images)

As the U.K. prepares to leave the EU, newly elected Prime Minister Boris Johnson has sketched out plans that aim to speed up trials.

Details are still thin, but the so-called Medicines and Medical Devices Bill will be brought forward by the Conservative government, which won a large majority in the general election just before Christmas.

There is a series of ideas in the bill that includes relaxing certain rules around studies and speeding up the approval of new medicines. This will create a “streamlined, internationally competitive” process for approving new drugs and devices, the government said, and would focus on “removing unnecessary bureaucracy” for what it deems low-risk clinical trials.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

The bill also aims to boost the range of professions able to prescribe medicines and to enable the Medicines and Healthcare products Regulatory Agency to develop approaches to respond quickly to developments such as the use of artificial intelligence in life sciences.

Last year, there were just under 1,000 clinical trials in the U.K., with more than 1 million patients taking part in research.

The aims of the bill, which will need to become law in order to be affected in the country, are to maintain a competitive edge on the global stage and to make the U.K.’s biopharma and contract research environment attractive for the future.

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19.